| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 01/15/2003 | EP1274692A1 Quinazoline compounds |
| 01/15/2003 | EP1274428A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274424A1 Compounds and methods |
| 01/15/2003 | EP1274415A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274408A2 Use of natural chrysanthone compounds having antiangiogenic activity |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 01/15/2003 | EP1169317B1 Triarylimidazoles |
| 01/15/2003 | EP1121929A4 Drug preparation "histochrome" for treating ocular conditions |
| 01/15/2003 | EP0954222A4 Gene therapy for proliferative vitreoretinopathy |
| 01/15/2003 | EP0925287B1 Heterocyclic metalloprotease inhibitors |
| 01/15/2003 | EP0749981B1 Monoclonal antibody specific for pd-ecgf / thymidine phosphorylase |
| 01/15/2003 | CN1391572A Oxazolidinones having sulfoximine functionality and their use as antimicrobial agents |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391562A Quinazoline derivatives as pharmaceuticals |
| 01/15/2003 | CN1391557A 6-position substituted indoline, production and use thereof as medicament |
| 01/15/2003 | CN1391481A 疫苗 Vaccine |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391475A Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 01/15/2003 | CN1098849C 噻唑衍生物 Thiazole derivatives |
| 01/14/2003 | US6506802 Disulfide derivatives useful for treating allergic diseases |
| 01/14/2003 | US6506788 N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002113A1 Vitamin c compositions |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | WO2003002098A1 Tablet comprising cetirizine and pseudoephedrine |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2002098345A8 Use of an antioxidant for treating and/or preventing surface ocular disorders |
| 01/09/2003 | WO2002083716A3 Type b botulism toxin inhibitors |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002060486A3 Controlled release microsphere system for administration of drug to the eye |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008910 Use of proteasome inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008899 For use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex |
| 01/09/2003 | US20030008889 Aminoadamantane derivatives as therapeutic agents |
| 01/09/2003 | US20030008886 For therapy of pain |
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008874 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008859 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/09/2003 | US20030008854 Use of NF-kappabeta inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008853 Administering 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3 alpha ,4 beta ,5 alpha , 6 alpha ,7 beta ,14 beta ,22S)-stigmastan-15-one and carrier for wetting eye |
| 01/09/2003 | US20030008834 Compsoitions and methods for treating epithelia and retinal tissue diseases |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2420548A1 Composition comprising vitamin c and a pyrone or furanone compound |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272638A2 Drug metabolizing enzymes |
| 01/08/2003 | EP1272530A1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/08/2003 | EP1272513A2 Neurogenic compositions and methods |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272489A1 Process for preparing crystalline form i of cabergoline |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272484A2 Benzoamide piperidine compounds as substance p antagonists |
| 01/08/2003 | EP1272470A1 Amorphous torasemide modification |
| 01/08/2003 | EP1272456A1 Hydrazide and alkoxyamide angiogenesis inhibitors |
| 01/08/2003 | EP1272455A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 01/08/2003 | EP1272201A2 Use of compatible solutes as substances having free radical scavenging properties |
| 01/08/2003 | EP1272200A1 Divided dose therapies with vascular damaging activity |
| 01/08/2003 | EP1272194A2 Composition for use in treatment of ocular hypertension and glaucoma |
| 01/08/2003 | EP1272186A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 01/08/2003 | EP1272185A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 01/08/2003 | EP1272175A2 Il-8 receptor antagonists |
| 01/08/2003 | EP1272170A1 Ocular growth and nicotinic antagonists |
| 01/08/2003 | EP1272058A2 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
| 01/08/2003 | EP1218407A4 Uses of kappa-conotoxin pviia |
| 01/08/2003 | EP1077945B1 Isoquinolines as urokinase inhibitors |
| 01/08/2003 | EP1021192B1 Dexamethasone gel |
| 01/08/2003 | EP1005358B1 Use of a neurturin protein product for preventing and treating hearing loss |
| 01/08/2003 | EP0946175B1 USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS |
| 01/08/2003 | EP0859622B1 Extracts of shark cartilage |
| 01/08/2003 | CN1390220A Kinase inhibitors as therapeutic agents |